Platelet mitochondrial membrane depolarization reflects disease severity in patients with preeclampsia.
Mitochondrial membrane potential
Platelets
Preeclampsia
Journal
Molecular medicine (Cambridge, Mass.)
ISSN: 1528-3658
Titre abrégé: Mol Med
Pays: England
ID NLM: 9501023
Informations de publication
Date de publication:
04 05 2022
04 05 2022
Historique:
received:
10
12
2021
accepted:
10
04
2022
entrez:
5
5
2022
pubmed:
6
5
2022
medline:
7
5
2022
Statut:
epublish
Résumé
Thrombocytopenia is a feared complication of preeclampsia (PE) that can additionally complicate the disease course and that carries a poor prognosis. The disease mechanisms of PE on a platelet level are poorly understood and only few platelet-based markers have been investigated. In sepsis, platelet mitochondrial membrane depolarization, a sensitive and early indicator of mitochondrial dysfunction and platelet cell death, correlates with disease severity and outcome as shown in previous studies. The aim of this study was to investigate platelet mitochondrial membrane potential (Mmp-Index) by flow-cytometry in patients with preeclampsia compared to controls and to assess its value in correlation with disease severity of PE and during follow-up after delivery. In this prospective translational case-control study, platelet Mmp-Index was measured in PE (n = 16) by flow cytometry in living platelets in simultaneous comparison to healthy pregnant (n = 32) and non-pregnant controls (n = 16) and was individually reassessed after delivery to investigate recovery of platelet mitochondrial function. Subgroup analysis of patients with severe and non-severe PE was performed. Six patients with isolated gestational hypertension were also included for comparative analysis. Platelet Mmp-Index in patients with symptomatic preeclampsia (Mmp-Index non-severe PE 0.72 ([0.591; 0.861]; p = 0.002) was significantly reduced compared to healthy pregnant controls (Mmp-Index 0.97 [0.795; 1.117]) and even more pronounced in patients with severe PE (n = 6) (Mmp-Index severe PE 0.542 [0.361; 0.623]; p = 0.03). In the severe PE group, complementary measurements of platelet Annexin V- and CD62 (P-Selectin) surface expression showed apoptosis of platelet populations in the majority of patients. Platelet Mmp normalized after delivery within few days. Patients with isolated gestational hypertension showed normal Mmp-Index values. This study shows for the first time that platelet Mmp-Index is a quantifiable, easy-to-measure intracellular marker of platelet mitochondrial function in vital cells that reflects disease severity of preeclampsia. For future investigations, platelet Mmp may serve as a prognostic marker that may aid clinical risk stratification and adds novel information on potential mechanisms for thrombocytopenia in preeclampsia.
Sections du résumé
BACKGROUND
Thrombocytopenia is a feared complication of preeclampsia (PE) that can additionally complicate the disease course and that carries a poor prognosis. The disease mechanisms of PE on a platelet level are poorly understood and only few platelet-based markers have been investigated. In sepsis, platelet mitochondrial membrane depolarization, a sensitive and early indicator of mitochondrial dysfunction and platelet cell death, correlates with disease severity and outcome as shown in previous studies. The aim of this study was to investigate platelet mitochondrial membrane potential (Mmp-Index) by flow-cytometry in patients with preeclampsia compared to controls and to assess its value in correlation with disease severity of PE and during follow-up after delivery.
METHODS
In this prospective translational case-control study, platelet Mmp-Index was measured in PE (n = 16) by flow cytometry in living platelets in simultaneous comparison to healthy pregnant (n = 32) and non-pregnant controls (n = 16) and was individually reassessed after delivery to investigate recovery of platelet mitochondrial function. Subgroup analysis of patients with severe and non-severe PE was performed. Six patients with isolated gestational hypertension were also included for comparative analysis.
RESULTS
Platelet Mmp-Index in patients with symptomatic preeclampsia (Mmp-Index non-severe PE 0.72 ([0.591; 0.861]; p = 0.002) was significantly reduced compared to healthy pregnant controls (Mmp-Index 0.97 [0.795; 1.117]) and even more pronounced in patients with severe PE (n = 6) (Mmp-Index severe PE 0.542 [0.361; 0.623]; p = 0.03). In the severe PE group, complementary measurements of platelet Annexin V- and CD62 (P-Selectin) surface expression showed apoptosis of platelet populations in the majority of patients. Platelet Mmp normalized after delivery within few days. Patients with isolated gestational hypertension showed normal Mmp-Index values.
CONCLUSIONS
This study shows for the first time that platelet Mmp-Index is a quantifiable, easy-to-measure intracellular marker of platelet mitochondrial function in vital cells that reflects disease severity of preeclampsia. For future investigations, platelet Mmp may serve as a prognostic marker that may aid clinical risk stratification and adds novel information on potential mechanisms for thrombocytopenia in preeclampsia.
Identifiants
pubmed: 35508969
doi: 10.1186/s10020-022-00472-x
pii: 10.1186/s10020-022-00472-x
pmc: PMC9066965
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
51Informations de copyright
© 2022. The Author(s).
Références
N Engl J Med. 2004 Feb 12;350(7):672-83
pubmed: 14764923
Obstet Gynecol. 2001 Mar;97(3):366-70
pubmed: 11239638
Biosci Rep. 2018 May 8;38(3):
pubmed: 29654168
Pregnancy Hypertens. 2018 Jul;13:242-247
pubmed: 30177059
Obstet Gynecol. 2019 Jan;133(1):1
pubmed: 30575675
Heart Lung. 2010 Jan-Feb;39(1):21-6
pubmed: 20109983
Am J Obstet Gynecol. 2014 Jun;210(6):547.e1-7
pubmed: 24440566
South Med J. 2000 Aug;93(8):768-71
pubmed: 10963506
J Anat. 2009 Jul;215(1):21-6
pubmed: 19215319
Int J Mol Sci. 2020 Jan 30;21(3):
pubmed: 32019243
Obstet Gynecol. 1994 Jan;83(1):146-9
pubmed: 8272297
Cell. 2007 Mar 23;128(6):1173-86
pubmed: 17382885
Lab Invest. 2009 Apr;89(4):374-84
pubmed: 19238135
Pregnancy Hypertens. 2017 Apr;8:1-5
pubmed: 28501272
Hematol Transfus Cell Ther. 2019 Apr - Jun;41(2):129-133
pubmed: 31084762
Front Immunol. 2020 Apr 15;11:667
pubmed: 32351511
Crit Care Med. 2002 Aug;30(8):1765-71
pubmed: 12163790
Acta Obstet Gynecol Scand. 2013 May;92(5):601-5
pubmed: 23506129
Am J Obstet Gynecol. 2004 Apr;190(4):1128-34
pubmed: 15118653
Redox Biol. 2014 Jan 10;2:206-10
pubmed: 24494194
Reprod Sci. 2021 Aug;28(8):2186-2199
pubmed: 33523425
Am J Hypertens. 2021 May 22;34(5):442-452
pubmed: 33417666
Reprod Biol Endocrinol. 2009 Jul 14;7:70
pubmed: 19602262
Br J Haematol. 2008 Jul;142(3):494-7
pubmed: 18492095
Crit Care. 2014 Feb 12;18(1):R31
pubmed: 24521521
J Thromb Haemost. 2009 Jul;7 Suppl 1:214-7
pubmed: 19630803
J Matern Fetal Neonatal Med. 2021 May;34(9):1407-1414
pubmed: 31257953
N Engl J Med. 1990 Aug 16;323(7):434-8
pubmed: 2374565
Crit Care Med. 2002 Apr;30(4):753-6
pubmed: 11940740
Hypertens Res. 2013 Sep;36(9):783-8
pubmed: 23575380
Br J Haematol. 2014 Apr;165(2):217-26
pubmed: 24467740
J Clin Lab Anal. 2012 Sep;26(5):403-6
pubmed: 23001987
Eur J Obstet Gynecol Reprod Biol. 2013 Sep;170(1):1-7
pubmed: 23746796
Blood. 2012 Dec 13;120(25):5014-20
pubmed: 23086749
Cell Death Dis. 2019 Dec 5;10(12):927
pubmed: 31804457
N Engl J Med. 2016 Jan 7;374(1):13-22
pubmed: 26735990
Pregnancy Hypertens. 2018 Jul;13:174-180
pubmed: 30177049
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619853641
pubmed: 31167567
J Perinat Med. 2006;34(3):246-7
pubmed: 16602847
Front Cardiovasc Med. 2020 Mar 03;7:15
pubmed: 32195268
Am J Obstet Gynecol. 1997 Feb;176(2):461-9
pubmed: 9065199
J Trauma Acute Care Surg. 2013 Feb;74(2):411-7; discussion 418
pubmed: 23354232
Br J Haematol. 2013 Apr;161(2):245-54
pubmed: 23398569